EQUILLIUM INC (EQ) Stock Price, Quote, News and Overview
NASDAQ:EQ - Nasdaq - US29446K1060 - Common Stock - Currency: USD
EQ Quote, Performance and Key Statistics
EQUILLIUM INC
NASDAQ:EQ (2/6/2025, 8:00:01 PM)
After market: 0.9198 -0.02 (-2.6%)0.9444
+0.23 (+33.03%)
The current stock price of EQ is 0.9444 USD. In the past month the price increased by 21.97%. In the past year, price decreased by -38.68%.
EQ Latest News, Press Releases and Analysis
Which stocks are moving on Thursday?
Curious about what's happening in today's session? Check out the latest stock movements and price changes.
Equillium Reports Third Quarter 2024 Financial Results and Provides Corporate and Clinical Updates
Equillium to Present at the Stifel Healthcare Conference
Equillium Announces Poster Presentation at the Society for Immunotherapy of Cancer
EQ Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 19.07 | 341.01B | ||
| AMGN | AMGEN INC | 15.02 | 160.07B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 943.45 | 123.91B | ||
| GILD | GILEAD SCIENCES INC | 22.13 | 122.18B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.82 | 79.35B | ||
| ARGX | ARGENX SE - ADR | N/A | 39.34B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 35.89B | ||
| BNTX | BIONTECH SE-ADR | N/A | 28.75B | ||
| ONC | BEIGENE LTD-ADR | N/A | 24.39B | ||
| NTRA | NATERA INC | N/A | 23.12B | ||
| BIIB | BIOGEN INC | 8.72 | 20.75B | ||
| UTHR | UNITED THERAPEUTICS CORP | 15.54 | 15.79B |
Related stock screener links
About EQ
Company Profile
Equillium, Inc. engages in the development of products for severe autoimmune and inflammatory, or immuno-inflammatory, disorders with high unmet medical need. The company is headquartered in La Jolla, California and currently employs 45 full-time employees. The company went IPO on 2018-10-12. The company is engaged in developing novel therapeutics to treat severe autoimmune and inflammatory disorders with high unmet medical need. The Company’s pipeline consists of immunomodulatory assets and a product platform targeting immuno-inflammatory pathways. The Company’s EQ101 is a selective tri-specific cytokine inhibitor targeting IL-2, IL-9, and IL-15. The EQ302 is an orally delivered, selective bi-specific cytokine inhibitor targeting IL-15 and IL-21. The company is in pre-clinical development. Its multi-cytokine platform generates rationally designed composite peptides that selectively block key cytokines at the shared receptor level targeting pathogenic cytokine redundancies and synergies while preserving non-pathogenic signaling. The Itolizumab is a monoclonal antibody that targets the CD6-ALCAM signaling pathway which plays a central role in the modulation of effector T cells.
Company Info
EQUILLIUM INC
2223 Avenida de La Playa Ste 105
La Jolla CALIFORNIA 92037 US
CEO: Bruce D. Steel
Employees: 45
Company Website: https://www.equilliumbio.com/home/default.aspx
Investor Relations: http://www.equilliumbio.com/investors/#investor-overview
Phone: 18584125302
EQ FAQ
What is the stock price of EQ?
The current stock price of EQ is 0.9444 USD.
What is the symbol for EQUILLIUM INC stock?
The exchange symbol of EQUILLIUM INC is EQ and it is listed on the Nasdaq exchange.
On which exchange is EQ stock listed?
EQ stock is listed on the Nasdaq exchange.
Is EQ a good stock to buy?
Always make your own analysis. On these pages you can find a full technical and fundamental analysis report for EQ, which may be a starting point for your analysis. You can also find the financials, news, analyst ratings and estimates here, which can be used to increase your understanding of EQ.
Does EQ stock pay dividends?
EQ does not pay a dividend.
What is the Price/Earnings (PE) ratio of EQ?
EQ does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.14).
What is the Short Interest ratio of EQ stock?
The outstanding short interest for EQ is 0.12% of its float.
EQ Technical Analysis
ChartMill assigns a technical rating of 4 / 10 to EQ. When comparing the yearly performance of all stocks, EQ is a bad performer in the overall market: 75.7% of all stocks are doing better.
EQ Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to EQ. EQ scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
EQ Financial Highlights
Over the last trailing twelve months EQ reported a non-GAAP Earnings per Share(EPS) of -0.14. The EPS increased by 41.67% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -13.39% | ||
| ROE | -19.91% | ||
| Debt/Equity | 0 |
EQ Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 85% to EQ. The Buy consensus is the average rating of analysts ratings from 12 analysts.
For the next year, analysts expect an EPS growth of 10.21% and a revenue growth 10.02% for EQ